Scoop: US to launch global health plans Congress hasn’t seen - Devex

IndigenousCourts countrywide are grappling with the complex question of whether federal and provincial governments can be sued for the stark overrepresentation of Indigenous children in the off-reserve child welfare system, delivering dizzyingly mixed results. Ontario court decision's statements on child welfare system called 'highly problematic'Brett Forester · CBC News · Posted: Oct 02, 2026 2:17 PM EDT | Last Updated: October 2Listen to this articleEstimated 5 minutesThe audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. The Supreme Court of Canada in Ottawa. (Benoit Roussel/Radio-Canada)No one disputes it: the statistics are stark. About eight per cent of the kids in Canada are Indigenous, yet more than half of the children in Canada's child welfare system are Indigenous. But can federal and provincial governments be sued for the overrepresentation of Indigenous kids in the off-reserve child welfare system? That's the dispute now unfolding in courts countrywide — with mixed results.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.